HTA & Market Access

All Items

• The value of obinutuzumab for untreated advanced Follicular Lymphoma: an assessment based on Multicriteria Decision Analysis (MCDA)

  Claudio Jommi, Roberto Ravasio

  78-85

  DOI: https://doi.org/10.33393/abtpn.2019.302

• Getting your devices ready for MDR compliance – a clinical approach and orthopaedic device manufacturers’ perspective

  Peter Fennema, Hassan Achakri

  70-75

  DOI: https://doi.org/10.33393/abtpn.2019.294

• Lean Management: organizational innovations in hematological Day-Hospitals Lean Management: innovazioni organizzative nei Day Hospital Ematologici

  Caterina Bianciardi, Jacopo Guercini

  62-69

  DOI: https://doi.org/10.33393/abtpn.2019.290

• Performance indicators for monitoring the integrated care pathway of patients with colorectal cancer: the E.Pic.A. project Performance indicators for colorectal cancer

  Andrea Ricotti, Giovanni Messori Ioli, Mattia Altini, Letizia Bachini, William Balzi, Giovanni Luca Frassineti, Fabrizio Gemmi, Ilaria Massa, Andrea Pierini, Oscar Bertetto, Patrizia Racca

  48-54

  DOI: https://doi.org/10.33393/abtpn.2019.292

• Key performance indicators for monitoring the integrated care pathway in breast cancer: the E.Pic.A. project

  Mattia Altini, William Balzi, Roberta Maltoni, Fabio Falcini, Flavia Foca, Giovanni Messori Ioli, Andrea Ricotti, Oscar Bertetto, Marinella Mistrangelo, Gianni Amunni, Fabrizio Gemmi, Letizia Bachini, Andrea Silenzi, Roberta Pastorino, Andrea Barbara, Andrea Pierini, Ilaria Massa

  31-38

  DOI: https://doi.org/10.33393/abtpn.2019.291

• A Budget impact analysis of adalimumab biosimilar: the Italian context Analisi di budget impact del biosimilare di adalimumab: lo scenario italiano

  Roberto Ravasio, Silvio Mazzi, Maria Esposito, Gionata Fiorino, Alberto Migliore

  16-23

  DOI: https://doi.org/10.33393/abtpn.2019.280